Phase 2 N=186 Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 Phase II Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025
Phase 2 N=50 Ranolazine Among Unrevascularized Chronic Stable Angina Patients
Angina
Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05
Phase 3 N=9,326 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Acute Coronary Syndrome
Primary: Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke — 10.06; 24.64; 10.96; 24.13 percentage of…
Phase 2 N=547 Safety Study of Apixaban in Recent Acute Coronary Syndrome
Acute Coronary Syndrome (ACS)
Primary: Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or…
Phase 1 N=64 A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
Angina Pectoris · Coronary Heart Disease · Calcitonin Gene-related Peptide Receptor
Primary: Number of Participants With Clinical Adverse Events (AEs) — 7; 1; 5 Participants
Phase 4 N=402 Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Stable Angina · Coronary Disease
Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001
Phase 4 N=3,235 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
Acute Coronary Syndrome
Primary: Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI Period — 48; 58 participants…
N/A N=90 Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)
Myocardial Infarction
Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05
Phase 3 N=2,651 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
Phase 4 N=949 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Angina Pectoris · Coronary Artery Disease · Type 2 Diabetes Mellitus
Primary: Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment — 5.2; 4.5 angina attacks per week — p=0.008
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
Phase 4 N=31 Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
Phase 4 N=171 An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
Chronic Angina
Primary: Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and…
Phase 2 N=53 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Critical Limb Ischemia
Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…
Phase 2 N=535 Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Myocardial Infarction · Acute Coronary Syndromes · Unstable Angina
Primary: The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding — 69; 60; 48 Participants
N/A N=200 Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
Stable Angina
Primary: Exercise Time on Treadmill — 28.4; 11.8 seconds
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 2 N=95 PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
Heart Failure · Myocardial Ischemia · Angina Pectoris
Primary: Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) — 0; 0; 1 Participants
Phase 4 N=110 Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: P2Y12 Reaction Units — 95.0; 49.0 PRU (P2Y12 Reaction Units)
Phase 2 N=36 Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Stable Angina
Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants
Phase 3 N=2,198 European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
Acute Coronary Syndrome
Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014
Phase 4 N=7,119 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Cardiovascular Disease · Interventional Cardiology
Primary: Number of Participants With BARC Type 2, 3, or 5 — 141; 250 Participants
N/A N=626 Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
Post Procedural Myocardial Infarction
Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants
N/A N=34 Comparative Effectiveness of Decision Aids for Stable Chest Discomfort
Coronary Artery Disease · Stable Angina
Primary: Total Knowledge Score — 2.83; 4.0 knowledge score
Phase 4 N=87 P3AMI Antiplatelet Trial
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
Phase 4 N=390 Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
Heart Disease · Myocardial Infarction · Acute Myocardial Infarction
Primary: Mortality at 30 Days — 1; 7; 3; 2 participants
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
N/A N=602 Early Risk Stratification in ED Chest Pain Patients
Acute Coronary Syndrome
Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants